Arcturus Therapeutics, Inc.

This was the first human study of a new type of mRNA flu vaccine designed to protect against potential future flu pandemics. Researchers tested three different doses in 212 healthy adults to see how safe it was and if it triggered a good immune response. They compared the new vac…

This was the first human study of a new seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology. It tested the vaccine's safety and ability to trigger an immune response in 139 healthy younger and older adults. The study compared different doses of the n…

This early-stage study tested three new COVID-19 RNA vaccine candidates in 72 healthy adults. It aimed to check their safety and how well they trigger an immune response in people who have never been vaccinated and in those who received previous COVID vaccines. Participants recei…

This large Phase 3 study tested a new type of COVID-19 booster vaccine (ARCT-2303) that uses self-amplifying RNA technology. Researchers wanted to see if it was safe and effective when given at the same time as a seasonal flu shot. The study involved over 1,500 adults who had alr…